William E. Dismukes, MD
The therapeutic armamentarium against both systemic and superficial fungal infections consists primarily of the polyenes, amphotericin B and nystatin; flucytosine, a fluorinated pyrimidine analogue; and the older antifungal azoles, clotrimazole, miconazole, and ketoconazole. Results of recent studies give promise that new investigational antifungal oral azole drugs, including itraconazole, fluconazole, and SCH 39304, will be exciting additions to current compounds. Although none of these new azoles has been approved by the Food and Drug Administration yet, two of them, itraconazole and fluconazole, have already been extensively studied in in-vitro and in-vivo animal model systems, and to a lesser degree in humans.
Learn more about subscription options.
Register Now for a free account.
Dismukes WE. Azole Antifungal Drugs: Old and New. Ann Intern Med. 1988;109:177–179. doi: 10.7326/0003-4819-109-3-177
Download citation file:
Published: Ann Intern Med. 1988;109(3):177-179.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only